Abstract
This study estimates the cost-effectiveness and budget impact of introducing ferric carboxymaltose (FCM) for the treatment of iron deficiency (ID) in patients with left ejection fraction (LVEF) <50%, stabilised after an episode of acute heart failure (AHF), from the perspective of healthcare payers in 5 European countries.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call